Nonopioid Drug For Acute Pain Wins FDA Approval

Boston:  A long-awaited nonopioid pain drug won approval yesterday from the U.S. Food and Drug Administration (FDA) to treat moderate to severe short-term pain. Suzetrigine, an oral drug marketed by Vertex Pharmaceuticals as Journavx, is the first to reach the market in a new class of pain treatments that avoid risks such as slowed breathing and the potential for addiction that come with opioid drugs such as oxycodone.

Rather than dulling pain by targeting the brain’s opioid receptors, suzetrigine works by blocking a sodium channel called Nav1.8 on pain-sensing nerves. Its development grew out of the discovery that people with genetic mutations that increase the channel’s activity suffered nerve pain even in the absence of injury.

Vertex announced last year that suzetrigine outperformed a placebo in its two pivotal trials, which involved people with pain after surgeries to remove bunions and excess abdominal fat. FDA has cleared the drug specifically for use in acute pain conditions, such as those after tissue injury from surgery or trauma.

Many in the field hope suzetrigine will also prove effective against harder to manage chronic pain conditions. But results Vertex announced last month from a phase 2 study, in people with the painful nerve condition lumbosacral radiculopathy, left some doubt. The study showed a reduction in pain among 102 people getting the drug, but also a similar pain reduction in 100 people who got a placebo. The company said it plans to proceed with a phase 3 trial designed to better control for the placebo effect, “pending discussions with regulators.”

Related Posts

  • Pharma
  • February 17, 2025
  • 74 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 69 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%